CER Daily Newsfeed

Atropos Health Launches Agentic AI for Clinical Evidence at Stanford Health Care

(10/28, Heather Landi, Fierce Healthcare) reports “...Atropos Health...is focused on filling the ‘evidence gap’ in healthcare by pulling relevant clinical data and generating real-world evidence at the point of care. At the HLTH conference, the company unveiled an agentic AI solution, called Evidence Agent, a personalized real-world evidence generator that integrates directly into electronic health records and clinicians' workflows.” Full

Rebates Play a Major Role in Whether Health Plans Restrict Access to Specialty Drugs | AMCP Nexus 2025

(10/27, Briana Contreras, Managed Healthcare Executive) reports “...The researchers expressed that greater transparency in rebate and pricing negotiations is crucial to promote equitable access to specialty drugs and to ensure affordability for patients across health plans. They suggested that policymakers and payers should examine PBM practices, including formulary management and rebate distribution, to better align financial incentives with patient access and overall healthcare value.” Full

Former W&M Aide: Another Plus To 340B Reform May Be Lower ACA Premiums

(10/27, Gabrielle Wanneh, Inside Health Policy) reports “...A former House Ways & Means staffer told Inside Health Policy that as Senate lawmakers craft a 340B reform bill, they should consider that the current drug discount program is contributing to higher Affordable Care Act (ACA) premiums and the way they craft the reforms could allow a possible extension of the expiring ACA enhanced subsidies to be more cost-effective. At issue are misaligned program incentives that encourage covered entities, primarily 340B hospitals, to prescribe more drugs and more expensive drugs to patients than is necessary.” Subscription Required

US FDA's Tidmarsh: Marginal Treatments Do More Harm Than Good

(10/27, Sarah Karlin-Smith, Pink Sheet) reports “...CDER Director George Tidmarsh called for industry to raise the bar on drug candidates, saying marginal treatments may do more harm than good. Tidmarsh said he wants to investigate endpoints used for accelerated approval to determine whether they are still appropriate. He also warned against using crossover designs for confirmatory studies.” Subscription Required